Alexion Pharmaceuticals to Present Data on Soliris (Eculizumab) andPNH at the 2007 American Society of Hematology (ASH) Annual Meeting
CHESHIRE, Conn., November 09, 2007 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. today announced that data relating to paroxysmal nocturnal hemoglobinuria (PNH), as well as to Soliris(R) (eculizumab) as a treatment for patients with PNH, have been published by the American Society of Hematology (ASH). Abstracts will be presented at the 2007 ASH annual meeting that is being held December 8 to 11, 2007 at the Georgia World Congress Center in Atlanta.
The following abstracts will be presented in a poster session on red cell regulation and disorders of production on Monday, December 10, 2007. The abstracts and presentation information can be accessed at the links provided below.
-- "High Incidence of Progression to Chronic Renal Insufficiency in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)" Dr. Peter Hillmen et al. http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5416 -- "Sustained Improvements in Transfusion Requirements, Fatigue and Thrombosis with Eculizumab Treatment in Paroxysmal Nocturnal Hemoglobinuria" Dr. Gerard Socie et al. http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5204 -- "Disease.Related Sy Symptoms Reported across a Broad Population of Patients with Paroxysmal Nocturnal Hemoglobinuria" Dr. Gabrielle Meyers et al. http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5438.
The following abstract will be presented in an oral session on red cell regulation and disorders of production on Tuesday, December 11, 2007. The abstract and presentation information can be accessed at the link provided below.
-- "Significant Disease Burden in Paroxysmal Nocturnal Hemoglobinuria Patients with Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion: Clinical Improvement with Eculizumab Therapy" Dr. Monica Bessler et al. http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5302. [ALXN-G]
CONTACT: Irving Adler, Sr. Director, Corporate Communications of AlexionPharmaceuticals, Inc., +1-203-272-8210; or Media, Mark Marmur of Makovsky &Company, +1-212-508-9670; or Investors, Rhonda Chiger of Rx Communications,+1-917-322-2569
Ticker Symbol: (NASDAQ-NMS:ALXN)
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: November 2007